Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·7h ago
More News
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $258.00 Price Target at Royal Bank Of Canada
Royal Bank Of Canada upped their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an "outperform" rating in a research note on Wednesday...
MarketBeat·2d ago
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.
Zacks·2d ago
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $265.00 Price Target at Wells Fargo & Company
Wells Fargo & Company raised their price objective on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an "overweight" rating in a research note on Wednesday...
MarketBeat·2d ago
Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Earnings Results, Beats Expectations By $1.67 EPS
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.67 by $1.67. Jazz Pharmaceuticals had a positive return on equity...
MarketBeat·3d ago
Jazz Pharmaceuticals Q1 Earnings Call Highlights
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported what executives repeatedly characterized as an exceptionally strong start to 2026, driven by double-digit growth across promoted brands and continued...
MarketBeat·3d ago
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3d ago
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of +35.91% and +9.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga·3d ago
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results PR Newswire DUBLIN, May 5, 2026 Strong commercial execution...